The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance.
Lu Si
No relevant relationships to disclose
Xiao wei Xu
No relevant relationships to disclose
Yan Kong
No relevant relationships to disclose
Keith T. Flaherty
No relevant relationships to disclose
Zhi Hong Chi
No relevant relationships to disclose
Chuan Liang Cui
No relevant relationships to disclose
Xi Nan Sheng
No relevant relationships to disclose
Si Ming Li
No relevant relationships to disclose
Bi Xia Tang
No relevant relationships to disclose
Jun Guo
No relevant relationships to disclose